Navigation Links
Regenicin Announces Closing of Private Placement Transaction
Date:11/11/2010

NEW YORK, Nov. 11, 2010 /PRNewswire-FirstCall/ -- Regenicin, Inc. (OTC Bulletin Board: RGIN) a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs, today announced the closing of a private placement. Regencin secured proceeds of $467,550.25. In addition the company converted $500,000 of debt into equity.

The proceeds, net of placement agent fees and expenses, will be used to continue to develop its innovative regenerative medicine platform.

This announcement is neither an offer to sell nor a solicitation of an offer to buy any of these securities and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful.

The securities have not been, and will not be, registered under the Securities Act of 1933, as amended, or any state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

About Regenicin

Regenicin, Inc. is a development stage biotechnology company. Regenicin is a publicly traded company, with headquarters in New York. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Regenicin(TM), Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville
2. Former Fujifilm Medical Systems USA Executive John J. Weber Agrees to Join Regenicin™ as a Member of Its Board of Directors and Interim CFO
3. Regenicin Names Former U.S. Marine Corp Operations Officer, Christopher Hadsall, Chief Operating Officer
4. Regenicin to Form Scientific Advisory Board
5. Regenicin Appoints Renowned New York Dermatologist, Dr. Gervaise Gerstner to Scientific Advisory Board
6. Regenicin to Present Live at RetailInvestorConferences.com on November 4th
7. Regenicin to Present at Event Celebrating Advancements in Regenerative Medicine
8. Regenicin Presentation Now Available Online at RetailInvestorConferences.com
9. Regenicin Changes Its Ticker Symbol to RGIN.OB
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
11. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... Md. , March 23, 2017  Northwest ... developing DCVax® personalized immune therapies for solid tumor ... the $7.5 million financing it announced last Friday, ... sold to several institutional investors securities totaling 28,843,692 ... per share, and 10,000,000 shares of Class C ...
(Date:3/23/2017)... Branford, CT (PRWEB) , ... March 23, 2017 ... ... Counsel, LLC, was recently selected by the Connecticut Technology Council (CTC) as a ... honored at CTC’s thirteenth annual Women of Innovation Awards Dinner. , The dinner ...
(Date:3/23/2017)... , March 23, 2017  Agriculture technology company ... A financing and note conversion to commercialize its Cool ... is focused on developing products that are simultaneously profitable ... million in the last 18 months. This latest round ... Bridge Venture Partners. The company,s primary ...
(Date:3/22/2017)... ... 2017 , ... Researchers face a fundamental challenge as they ... tissues, bones, even whole organs to implant in people to treat disease or ... the developing tissue. , Current bioengineering techniques, including 3-D printing, can’t fabricate ...
Breaking Biology Technology:
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
(Date:2/21/2017)... , February 21, 2017 ... 70 Millionen US-Dollar wachsen. Nach einem Gespräch mit mehr als ... einige Hindernisse zu überwinden gilt, um diese Prognose zu ... ... anderem die Mobilisierung der finanziellen Mittel für die Biobank, ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):